718 844
References
[1]
Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int 2011;107:1059–64.[2]
Tanaka N, Kikuchi E, Kanao K, et al. Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi- institutions. BJU Int 2013;112:E28–34.[3]
Roupreˆt M, Babjuk M, Compe´rat E, et al. European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 2015;68:868–79.[4]
Seisen T, Sun M, Leow JJ, et al. Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: a propensity score-weighted analysis from the National Cancer Data Base. J Clin Oncol 2016;34:3529–36.[5]
Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014;33:1242–58.[6]
Cole SR, Herna´ n MA. Adjusted survival curves with inverse prob- ability weights. Comput Methods Programs Biomed 2004;75: 45–9.[7]
Fossati N, Trinh Q-D, Sammon J, et al. Identifying optimal candi- dates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol 2015;67:3–6.[8]
Kaag MG, O’Malley RL, O’Malley P, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 2010;58:581–7.[9]
Kaag M, Trost L, Thompson RH, et al. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int 2014;114:674–9.[10]
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 7 1 4 – 7 1 8
718